Fundraising Fox
/Companies
Sign in

Onco Precision

Founded 2020 · 15 employees on LinkedIn · 4 known investors

Find your way into Onco Precision

Sign up to see every warm intro you have to Onco Precision

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Onco Precision team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.

AI & Machine LearningBiotechMedical Devices

Founders & leadership

Onco Precision was founded in 2020 by Gastón Soria.

GSGastón Soria
Gastón SoriaCo-Founder & CSOGastón Soria is Co-Founder and Chief Scientific Officer of OncoPrecision, a precision oncology company developing antibody-drug conjugates and bispecific antibodies for blood cancers and hard-to-treat solid tumors. He spent nearly two decades in academia, with expertise in cell-based synthetic lethality systems for drug and target discovery.

Investors · 4

Creative Ventureslisted by Creative VenturesSan Francisco Bay Area · $1M

How we know: Creative Ventures's portfolio page · a partner's Signal profile · funding news · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us

GRIDXlisted by GRIDXBuenos Aires · $250K

How we know: GRIDX's portfolio page · Not right? Tell us

SOSVlisted by SOSVNew York · $30K – $550K

How we know: funding news · open dataset · 5k.vc investor directory · sosv.com · Not right? Tell us

Related companies · 4

OncosenxOncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity. Its system pairs a patented Proteo-Lipid Vehicle (PLV) delivery agent with plasmid DNA payloads that induce apoptosis in cancer cells while sparing adjacent cells.
Oncusp TherapeuticsOnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.
Oncotelic TherapeuticsOncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
OncOnc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.

Companies working in the same space as Onco Precision.

In the news

OncoPrecision Raises $3.3M in Seed Fundingfinsmes.com · Nov 2022

Frequently asked questions

What does Onco Precision do?
OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.
Who founded Onco Precision?
Onco Precision was founded by Gastón Soria in 2020.
Who are Onco Precision's investors?
Onco Precision's investors include AIR Capital, Creative Ventures, GRIDX, SOSV.